論文

2021年3月18日

DA-EPOCH-R therapy for high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in a patient with renal dysfunction.

Journal of clinical and experimental hematopathology : JCEH
  • Masaki Mitobe
  • Keisuke Kawamoto
  • Takaharu Suzuki
  • Tatsuya Suwabe
  • Yasuhiko Shibasaki
  • Masayoshi Masuko
  • Kanako Inoue
  • Hiroaki Miyoshi
  • Koichi Ohshima
  • Hirohito Sone
  • Jun Takizawa
  • 全て表示

61
1
開始ページ
42
終了ページ
47
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.3960/jslrt.20043

High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, also known as double-hit lymphoma, has been reported as refractory to R-CHOP therapy and requires more intensive regimens. However, intensive and safe regimens for patients with renal dysfunction are unknown. Herein, we report the successful use of DA-EPOCH-R therapy for double-hit lymphoma in a 64-year-old man with renal dysfunction. The patient had lymphoma-induced bilateral ureteral obstruction. Although renal dysfunction remained after removing the obstruction using R-CHOP therapy, we completed six cycles of DA-EPOCH-R therapy without any major adverse events. DA-EPOCH-R therapy may be a safe regimen for renal dysfunction patients.

リンク情報
DOI
https://doi.org/10.3960/jslrt.20043
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/33551436
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053571
ID情報
  • DOI : 10.3960/jslrt.20043
  • PubMed ID : 33551436
  • PubMed Central 記事ID : PMC8053571

エクスポート
BibTeX RIS